Astellas Pharma Inc - Sales In U.S. Of Izervay (Avacincaptad Pegol Intravitreal Solution) For Treatment Of Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration In Q1 Of Fy2025 Was ¥15.9 Billion/ $110 Million
ReutersJul 9, 2025 11:32 PM
July 10 (Reuters) - Astellas Pharma Inc 4503.T:
ASTELLAS PHARMA INC: SALES IN U.S. OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) FOR TREATMENT OF GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION IN Q1 OF FY2025 WAS ¥15.9 BILLION/ $110 MILLION
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
[Reuters Analysis] Trump's antitrust enforcers 'get out of the way' of multibillion-dollar deals
July 10 (Reuters) - President Donald Trump's antitrust enforcers recently cleared a string of multibillion-dollar deals in a week, demonstrating a willingness to settle with companies that marks a shift from the Biden administration.Reuters
20 minutes ago
[Reuters Analysis] Brazil has few exit routes from Trump tariff but feels less pain
BRASILIA, July 10 (Reuters) - When U.S. President Donald Trump linked 50% tariffs on Brazil to the trial against his ally, the country's former far-right leader, Washington left Latin America's largest economy with few options to deescalate but may have overestimated the country's vulnerability to tReuters
20 minutes ago
Q2 2025 Earnings Season Preview: The First Test Under Trump’s Tariffs — Could Low Expectations Bring Surprises?
TradingKey - Mid-July will mark the first earnings season since President Donald Trump’s tariff policy took effect, offering investors a glimpse into how American companies are handling the impact of trade tensions. Analysts believe that with low expectations heading into Q2, it may be easier forTradingKey
Wed, Jul 9
Japan: Yen Likely to Rise or Stabilise, Unlikely to Fall, with High Odds for Bulls
TradingKey - We anticipate a high likelihood of the Japanese yen appreciating in the short term (0-3 months). This outlook is driven by two key factors: First, the diverging monetary policies of the U.S. and Japan (Federal Reserve rate cuts paired with Bank of Japan rate hikes) will support the...TradingKey
Mon, Jul 7
Prediction! Federal Reserve Chairman Jerome Powell's Next Move Will Be an Interest Rate Cut
The Federal Reserve must balance the risks of higher inflation with the risks of higher unemployment when making decisions on interest rates.Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »*Stock prices used were..The Motley Fool
Thu, Jun 26
Tradingkey
